朱曼

研究领域(方向):

抗肿瘤药物药理、中药药效物质基础分析

个人及工作简历(个人受教育及工作经历):

教育经历:

2015-09至2020-09,西安交通大学,药物分析学,博士

2011-09至2015-06,西北大学,中药学,学士

工作经历:

2024-10至今,西安交通大学,药学院,副教授

2020-11至2024-10,西安交通大学,药学院,助理教授

主要科研项目

(1)国家自然科学基金委员会,青年科学基金项目,82104213,斑蝥素调控IL-2Rα逆转皮肤T细胞淋巴瘤伏立诺他耐药作用研究,2022-01-01至2024-12-31,30万元,主持

(2)陕西省科技厅,陕西省重点研发计划项目,2024SF-YBXM-145,黄芪甲苷通过RON/β-catenin信号轴诱导肿瘤相关巨噬细胞极化抗肝癌转移作用研究,2024-01至2025-12,6万元,主持

(3)西安交通大学医学“基础-临床”融合创新项目,YXJLRH2022038,基于IL-2Rα的组蛋白乙酰化修饰研究斑蝥素逆转皮肤T细胞淋巴瘤伏立诺他耐药作用,2022-09-01至2024-8-31,20万元,主持

(4)西安交通大学,基本科研业务费自由探索与创新-教师类项目,xzy012022119,STING诱导巨噬细胞极化在香草酸抗乳腺癌中作用研究,2022-01至2023-12,10万元,主持

(5)中国博士后科学基金,中国博士后科学基金第78批面上资助,基于CPT1A介导的MDH2琥珀酰化修饰探讨黄芪甲苷逆转非小细胞肺癌联合化疗耐药的作用机制,2025M783941,2025.07至2027.06,8万元,主持

(6)陕西省博士后科研项目三等资助,GFPT2通过HSPD1 O-G1cNAc修饰调节线粒体稳态介导非小细胞肺癌联合化疗耐药的机制研究,2026.01至2027.12,5万元,主持

学术及科研成果、专利、论文

发表学术论文30余篇,其中以第一/共同第一作者在Journal for ImmunoTherapy of Cancer、Pharmacological Research、ACS Nano、Cell Death & Disease、Biochemical Pharmacology、Clinical and Translational Medicine、Molecular Oncology、Advanced Materials、Biomaterials等期刊发表SCI论文14篇;会议论文5篇;授权发明专利2项;授权软件著作权2项。

代表性论文:

  1. Man Zhu, Xiaoyu Tang, Zeren Zhu, Wenjun Tang, Yumeng Cheng, Wenjuan Tang, Qianqian Zhang, Longyu Qin, Suyu Zhang, Yanmin Zhang*. STING-driven mitochondrial metabolism reverses cisplatin resistance via MDH2 desuccinylation in non-small cell lung cancer, Journal of Advanced Research, 2026. doi: 10.1016/j.jare.2026.03.032.

  2. Man Zhu, Xiaoyu Tang, Zeren Zhu, Wenjun Tang, Yumeng Cheng, Wenjuan Tang, Qianqian Zhang, Longyu Qin, Yu Yao, Yanmin Zhang*. GFAT2-mediated HSPD1 O-GlcNAcylation drives chemotherapy resistance in non-small cell lung cancer, Journal of Experimental & Clinical Cancer Research, 2026,45:110.

  3. Man Zhu, Wenjun Tang, Xiaoyu Tang, Zeren Zhu, Yina Jiang, Ammar Sarwar, Hongmei Zhang, Dake Chu, Zixi Zhang*, Yanmin Zhang*. Cantharidin overcomes IL- 2Rα signaling-mediated vorinostat resistance in cutaneous T- cell lymphoma through reactive oxygen species, Journal for ImmunoTherapy of Cancer, 2024,12:e009099.

  4. Li Chen#,Man Zhu#, Handan Zhang, Wenjun Tang, Jie Liu, Xiaoyu Tang, Xiaowei Chang, Zeren Zhu, Tao Liu, Lin Weng, Yanmin Zhang*, XinChen*. Remodeling of effector and regulatory t cells by capture and utilization of miRNAs using nanocomposite hydrogel for tumor-specific photothermal immunotherapy. ACS Nano. 2025, 19:14873-14892.

  5. Man Zhu, Xiaoyu Tang, Zeren Zhu, Zhengyan Gong, Wenjuan Tang, Yu Hu, Cheng Cheng, Hongying Wang, Ammar Sarwar, Yanbin Chen, Feng Liu, Jian Huo, Xuemei Wang, Yanmin Zhang*. STING activation in macrophages by vanillic acid exhibits antineoplastic potential, Biochemical Pharmacology. 2023,213:115618.

  6. Tao Liu#,Man Zhu#, Xiaowei Chang, Xiaoyu Tang, Pingyun Yuan, Ran Tian, Zeren Zhu, Yanmin Zhang*, Xin Chen*. Tumor-specific photothermal-therapy-assisted immunomodulation via multiresponsive adjuvant nanoparticles. Advanced Materials. 2023, 35:e202300086.

  7. Weina Ma#,Man Zhu#, Bo Wange, Zhengyan Gong, Xia Du, Tianfeng Yang, Xianpeng Shi, Bingling Dai, Yingzhuan Zhan, Dongdong Zhang, Yanhong Ji, Yang Wang, Song Li*, Yanmin Zhang*. Vandetanib drives growth arrest and promotes sensitivity to imatinib in hematologic malignancies chronic myeloid leukemia by targeting ephrin type-B receptor 4. Molecular Oncology, 2022,16:2747-2765.

  8. Man Zhu, Xianpeng Shi, Zhengyan Gong, Qi Su, Runze Yu, Bo Wang, Tianfeng Yang, Bingling Dai, Yingzhuan Zhan, Dongdong Zhang, Yanmin Zhang*. Cantharidin treatment inhibits hepatocellular carcinoma development by regulating the JAK2/STAT3 and PI3K/Akt pathways in an EphB4-dependent manner, Pharmacological Research. 2020, 158:104868.

  9. Man Zhu, Zhengyan Gong, Qing Wu, Xianpeng Shi, Qi Su, Yanmin Zhang*. Sanguinarine suppresses migration and metastasis in colorectal carcinoma associated with the inversion of EMT through the Wnt/β-catenin signaling, Clinical and Translational Medicine, 2020,10:1-12.

  10. Man Zhu, Yuxin Cui, Liu Yang, Tianfeng Yang, Hongying Wang, Dongdong Zhang, Weina Ma*, Yanmin Zhang*. Ephrin type-B receptor 4 affinity chromatography: An effective and rapid method studying the active compounds targeting Ephrin type-B receptor 4, Journal of Chromatography A, 2019,1586:82-90.

科研获奖:

2025年获国家资助博士后研究人员计划C档

2021年获陕西省科学技术二等奖一项(R7)

2021年获陕西省高等学校技术一等奖一项(R7)

2023年获陕西省优秀博士学位论文

联系方式

电子邮箱:zm2020@xjtu.edu.cn

联系电话:

个人主页:

联系地址:

 

上一篇:丁正伟
下一篇:南冠君

地址:陕西省西安市咸宁西路28号 邮编:710049
版权所有:西安交通大学 站点建设与维护: 网络信息中心 陕ICP备06008037号